Page 22 - TD-3-3

Tumor Discovery Immune and epigenetic therapies for TNBC

chemotherapy-treated triple-negative breast cancer patients. via regulating TIMP2-MMP-2/-9 pathway. Am J Cancer Res.
NPJ Breast Cancer. 2016;2(1):16033. 2018;8:422-434.
doi: 10.1038/npjbcancer.2016.33 74. Yang H, Salz T, Zajac-Kaye M, Liao D, Huang S, Qiu Y.
Overexpression of histone deacetylases in cancer cells
63. Noy R, Pollard JW. Tumor-associated macrophages: From
mechanisms to therapy. Immunity. 2014;41:49-61. is controlled by interplay of transcription factors and
epigenetic modulators. FASEB J. 2014;28(10):4265-4279.
doi: 10.1016/j.immuni.2014.06.010
doi: 10.1096/fj.14-250654
64. Hollmén M, Karaman S, Schwager S, et al. G-CSF
regulates macrophage phenotype and associates with poor 75. Title AC, Silva PN, Godbersen S, Hasenöhrl L, Stoffel M. The
overall survival in human triple-negative breast cancer. miR-200-Zeb1 axis regulates key aspects of β-cell function
Oncoimmunology. 2016;5(3):e1115177. and survival in vivo. Mol Metab. 2021;53:101267.
doi: 10.1016/j.molmet.2021.101267
doi: 10.1080/2162402X.2015.1115177
65. Jamiyan T, Kuroda H, Yamaguchi R, Abe A, Hayashi M. 76. Miller TE, Ghoshal K, Ramaswamy B, et al.
CD68- and CD163-positive tumor-associated macrophages MicroRNA-221/222 confers tamoxifen resistance
in triple negative cancer of the breast. Virchows Arch. in breast cancer by targeting p27Kip1. J Biol Chem.
2020;477:767-775. 2008;283(44):29897-29903.
doi: 10.1007/s00428-020-02855-z doi: 10.1074/jbc.M804612200
66. Wang J, Chen H, Chen X, Lin H. Expression of tumor- 77. Zhang Z, Zhou C, Li X, et al. Loss of CHD1 promotes
related macrophages and cytokines after surgery of triple- heterogeneous mechanisms of resistance to AR-targeted
negative breast cancer patients and its implications. Med Sci therapy via chromatin dysregulation. Cancer Cell.
Monit. 2016;22:115-120. 2020;37(4):584-598.e11.
doi: 10.12659/msm.895386 doi: 10.1016/j.ccell.2020.03.001
67. Niu M, Valdes S, Naguib YW, Hursting SD, Cui Z. Tumor- 78. Cortazar P, Zhang L, Untch M, et al. Pathological complete
associated macrophage-mediated targeted therapy of triple- response and long-term clinical benefit in breast cancer: The
negative breast cancer. Mol Pharm. 2016;13(6):1833-1842. CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-172.
doi: 10.1021/acs.molpharmaceut.5b00987 doi: 10.1016/S0140-6736(13)62422-8
68. Rogers TL, Holen I. Tumour macrophages as potential 79. Kagihara JA, Andress M, Diamond JR. Nab-paclitaxel
targets of bisphosphonates. J Transl Med. 2011;9:177. and atezolizumab for the treatment of PD-L1-positive,
metastatic triple-negative breast cancer: Review and future
doi: 10.1186/1479-5876-9-177 directions. Expert Rev Precis Med Drug Dev. 2020;5(2):59.
69. Yang Q, Guo N, Zhou Y, Chen J, Wei Q, Han M. The role doi: 10.1080/23808993.2020.1730694
of tumor-associated macrophages (TAMs) in tumor
progression and relevant advance in targeted therapy. Acta 80. Adams S, Schmid P, Rugo HS, et al. Pembrolizumab
Pharm Sin B. 2020;10:2156-2170. monotherapy for previously treated metastatic triple-
negative breast cancer: Cohort A of the phase II
doi: 10.1016/j.apsb.2020.04.004 KEYNOTE-086 study. Ann Oncol. 2019;30(3):397-404.
70. Panjarian S, Issa JPJ. The roles of DNA demethylases in doi: 10.1093/annonc/mdy517
triple-negative breast cancer. Pharmaceuticals (Basel).
2021;14:628. 81. Ozaki Y, Matsumoto K, Takahashi M, et al. Phase II study
of a combination therapy of nivolumab, bevacizumab and
doi: 10.3390/ph14070628
paclitaxel in patients with HER2-negative metastatic breast
71. Malpeli G, Innamorati G, Decimo I, et al. Methylation cancer as a first-line treatment (WJOG9917B, NEWBEAT
dynamics of RASSF1A and its impact on cancer. Cancers trial). J Clin Oncol. 2018;36(15_suppl):TPS1110.
(Basel). 2019;11:959. doi: 10.1016/j.ejca.2022.05.014
doi: 10.3390/cancers11070959 82. Chen F, Chen N, Gao Y, Jia L, Lyu Z, Cui J. Clinical progress
72. Saelee P, Pongtheerat T. APC promoter hypermethylation as of PD-1/L1 inhibitors in breast cancer immunotherapy.
a prognostic marker in breast cancer patients. Asian Pac J Front Oncol. 2022;11:724424.
Cancer Prev. 2020;21(12):3627-3632.
doi: 10.3389/fonc.2021.724424
doi: 10.31557/APJCP.2020.21.12.3627 83. Li Y, Zhang H, Merkher Y, et al. Recent advances in
73. Chien YC, Liu LC, Ye HY, Wu JY, Yu YL. EZH2 promotes therapeutic strategies for triple-negative breast cancer.
migration and invasion of triple-negative breast cancer cells J Hematol Oncol. 2022;15:121.

Volume 3 Issue 3 (2024) 16 doi: 10.36922/td.3383